A pilot study of a ketogenic diet in patients with Lafora body disease

被引:58
作者
Cardinali, Simonetta
Canafoglia, Laura
Bertoli, Simona
Franceschetti, Silvana
Lanzi, Giovanni
Tagliabue, Anna
Veggiotti, Pierangelo
机构
[1] Fdn C Mondino Inst Neurol, Child EEG Unit, Dept Child Neuropsychiat, I-27100 Pavia, Italy
[2] Ist Nazl Neurol Carlo Besta, Dept Neurophysiopathol, Milan, Italy
[3] Ist Nazl Neurol Carlo Besta, Epilepsy Ctr, Milan, Italy
[4] Univ Milan, Int Ctr Assessment Nutr Status, Dept Food Sci Technol & Microbiol, Milan, Italy
[5] Univ Pavia, Dept Hlth Sci, I-27100 Pavia, Italy
关键词
Lafora disease; ketogenic diet; therapy; neurophysiological findings; neuropsychological evolution;
D O I
10.1016/j.eplepsyres.2006.01.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Lafora body disease (LBD) is severe and rapidly worsening progressive myoclonus epilepsy (PME), not treatable with specific therapy. In LBD patients, typical polyglucosan accumulations result from alterations of proteins involved in the regulation of glycogen metabolism. Thus, a ketogenic regimen might reasonably be expected to counteract the disease progression. We set out to assess the feasibility and tolerability of a long-term ketogenic diet (KD) in LBD patients and to make a preliminary evaluation of its effect on the disease course. Methods: We treated five LBD patients with KD and evaluated the changes in the clinical, neuropsychological and neurophysiological findings over 10-30 months. Results: The KD was well tolerated in all the patients for the first 16 months. Nutritional measures and laboratory findings remained substantially stable. The disease progressed in all the patients, reaching an advanced stage in one. Electrophysiological findings indicated the presence of increased cortical excitability in four patients, paralleling the worsening of the myoclonus. Conclusion: KD was unable to stop the disease progression. However, given the considerable heterogeneity of the natural history of LBD. we cannot exclude the possibility that KD has the potential to slow down the disease progression. The application of this nutritional approach should be further evaluated in larger case series. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:129 / 134
页数:6
相关论文
共 13 条
[1]   A novel exon 1 mutation in a patient with atypical Lafora progressive myoclonus epilepsy seen as childhood-onset cognitive deficit [J].
Annesi, G ;
Sofia, V ;
Gambardella, A ;
Candiano, ICC ;
Spadafora, P ;
Annesi, F ;
Cutuli, N ;
De Marco, EV ;
Civitelli, D ;
Carrideo, S ;
Tarantino, P ;
Barone, R ;
Zappia, M ;
Quattrone, A .
EPILEPSIA, 2004, 45 (03) :294-295
[2]   Periventricular nodular heterotopia: Classification, epileptic history, and genesis of epileptic discharges [J].
Battaglia, G ;
Chiapparini, L ;
Franceschetti, S ;
Freri, E ;
Tassi, L ;
Bassanini, S ;
Villani, F ;
Spreafico, R ;
D'Incerti, L ;
Granata, T .
EPILEPSIA, 2006, 47 (01) :86-97
[3]  
Bertoli S., 2005, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V5, P113, DOI 10.2174/1568013053586397
[4]   Sensorimotor cortex excitability in Unverricht-Lundborg disease and Lafora body disease [J].
Canafoglia, L ;
Ciano, C ;
Panzica, F ;
Scaioli, V ;
Zucca, C ;
Agazzi, P ;
Visani, E ;
Avanzini, G ;
Franceschetti, S .
NEUROLOGY, 2004, 63 (12) :2309-2315
[5]   Progressive myoclonus epilepsy with polyglucosans (Lafora disease) - Evidence for a third locus [J].
Chan, EM ;
Omer, S ;
Ahmed, M ;
Bridges, LR ;
Bennett, C ;
Scherer, SW ;
Minassian, BA .
NEUROLOGY, 2004, 63 (03) :565-567
[6]   Mutations in NHLRC1 cause progressive myoclonus epilepsy [J].
Chan, EM ;
Young, EJ ;
Ianzano, L ;
Munteanu, I ;
Zhao, XC ;
Christopoulos, CC ;
Avanzini, G ;
Elia, M ;
Ackerley, CA ;
Jovic, NJ ;
Bohlega, S ;
Andermann, E ;
Rouleau, GA ;
Delgado-Escueta, AV ;
Minassian, BA ;
Scherer, SW .
NATURE GENETICS, 2003, 35 (02) :125-127
[7]   Laforin, the dual-phosphatase responsible for Lafora disease, interacts with R5 (PTG), a regulatory subunit of protein phosphatase-1 that enhances glycogen accumulation [J].
Fernández-Sánchez, ME ;
Criado-García, O ;
Heath, KE ;
García-Fojeda, B ;
Medraño-Fernández, I ;
Gomez-Garre, P ;
Sanz, P ;
Serratosa, JM ;
de Córdoba, SR .
HUMAN MOLECULAR GENETICS, 2003, 12 (23) :3161-3171
[8]  
Footitt DR, 1997, J NEUROL, V244, P40
[9]   Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice [J].
Ganesh, S ;
Delgado-Escueta, AV ;
Sakamoto, T ;
Avila, MR ;
Machado-Salas, J ;
Hoshii, Y ;
Akagi, T ;
Gomi, H ;
Suzuki, T ;
Amano, K ;
Agarwala, KL ;
Hasegawa, Y ;
Bai, DS ;
Ishihara, T ;
Hashikawa, T ;
Itohara, S ;
Cornford, EM ;
Niki, H ;
Yamakawa, K .
HUMAN MOLECULAR GENETICS, 2002, 11 (11) :1251-1262
[10]   Worldwide use of the ketogenic diet [J].
Kossoff, EH ;
McGrogan, JR .
EPILEPSIA, 2005, 46 (02) :280-289